Nevertheless, a phase II trial evaluating nivolumab combined with the CD40 agonist sotigalimab in patients with melanoma resistant to prior immune checkpoint inhibitors demonstrated a modest 15% overall response rate [35]. This evidence concerns the gene CD40 and melanoma.